Thomas Illingworth


NameThomas Illingworth
Job titleLecturer in Biomedical Sciences & Public Health
Research instituteCollege of Science and Engineering
ORCIDhttps://orcid.org/0000-0001-9762-5071

Research outputs

Targeting hPKM2 in cancer: a bio isosteric approach for ligand design

Pipitò.L, Illingworth, T.A and Deganutti.G 2023. Targeting hPKM2 in cancer: a bio isosteric approach for ligand design. Computers in Biology and Medicine. 158, pp. 1-9. https://doi.org/10.1016/j.compbiomed.2023.106852

Bacterial Interactions Affecting Chemotherapy Effectiveness

Chambers, J.M and Illingworth, T. 2023. Bacterial Interactions Affecting Chemotherapy Effectiveness. McGill Science Undergraduate Research Journal. 18 (1), pp. 15 - 18. https://doi.org/10.26443/msurj.v18i1.190

Development and validation of anti-human Alpha synuclein DNA aptamer using computer modelling techniques—an in silico study

Rock, M., Zouganelis, G., Belchior de Andrade, A., Drake, S., Alexiou, A., Albrakati, A., Bathia, G. E. S. and Illingworth, T. 2022. Development and validation of anti-human Alpha synuclein DNA aptamer using computer modelling techniques—an in silico study. Journal of Integrative Neuroscience. 21 (1), p. 5. https://doi.org/10.31083/j.jin2101005

The formyl peptide receptor agonist FPRa14 induces differentiation of Neuro2a mouse neuroblastoma cells into multiple distinct morphologies which can be specifically inhibited with FPR antagonists and FPR knockdown using siRNA

Howe, Michael, Illingworth, Thomas, Milton, Nathaniel, Paterson, Andrew, Gomez-Escalada, Margarita and Cussell, Peter.J.G 2019. The formyl peptide receptor agonist FPRa14 induces differentiation of Neuro2a mouse neuroblastoma cells into multiple distinct morphologies which can be specifically inhibited with FPR antagonists and FPR knockdown using siRNA. PLos ONE. https://doi.org/10.1371/journal.pone.0217815
  • 113
    total views of outputs
  • 60
    total downloads of outputs
  • 10
    views of outputs this month
  • 1
    downloads of outputs this month